openPR Logo
Press release

Theranostics Market to Reach USD 12.5 Billion by 2034

11-11-2025 12:53 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Theranostics

Theranostics

The Global Theranostics Market is poised for remarkable growth as healthcare systems embrace precision medicine, combining diagnostics and therapy into unified treatment pathways. According to Exactitude Consultancy, the market, valued at USD 5.3 billion in 2024, is projected to reach USD 12.5 billion by 2034, growing at an impressive CAGR of 9.1 % during the forecast period (2025-2034).

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49320

Driven by advances in molecular imaging, radiolabeled drugs, and companion diagnostics, theranostics is transforming cancer treatment, particularly in oncology and nuclear medicine.

Key Takeaways
• Market Size: USD 5.3 billion (2024) → USD 12.5 billion (2034)
• CAGR: 9.1 % (2025-2034)
• Dominant Segment: Oncology applications account for over 70 % of market revenue
• Emerging Focus: Neurodegenerative and cardiovascular diseases
• Leading Regions: North America dominates; Asia-Pacific expected to exhibit fastest growth

Market Story
Theranostics - the convergence of diagnostics and therapeutics - is revolutionizing how clinicians detect, monitor, and treat diseases.
By linking diagnostic imaging with targeted therapy, theranostic agents enable real-time tracking of treatment efficacy, reducing trial-and-error medicine.

The growing success of radiotheranostic drugs such as Lutathera® (lutetium Lu 177 dotatate) and Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in cancer care has accelerated global adoption.

These agents target specific tumor biomarkers, delivering radiation directly to cancer cells while minimizing harm to healthy tissue.

Beyond oncology, research in neurotheranostics (for Alzheimer's and Parkinson's) and cardiovascular molecular imaging is opening new frontiers for early diagnosis and personalized intervention.

Segmentation Overview
By Product Type
• Radiopharmaceuticals
• Companion Diagnostics
• Imaging Agents
• Therapeutic Agents

By Application
• Oncology (Prostate, Neuroendocrine, Breast, Lung, Thyroid)
• Neurology
• Cardiovascular Disorders
• Autoimmune & Inflammatory Diseases
• Others

By End User
• Hospitals
• Diagnostic Imaging Centers
• Research & Academic Institutes
• Pharmaceutical & Biotech Companies

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/49320/theranostics-market

Recent Developments
• Novartis AG expanded production of its FDA-approved radioligand therapies Pluvicto® and Lutathera® to meet surging oncology demand.
• GE HealthCare launched a new PET/CT imaging platform optimized for theranostic workflow integration.
• Telix Pharmaceuticals Ltd. received regulatory approval for Illuccix® (68Ga-PSMA-11), a prostate cancer diagnostic radiopharmaceutical.
• Bayer AG announced the development of targeted alpha therapies (TATs) using actinium-based isotopes for advanced solid tumors.
• Siemens Healthineers introduced AI-driven molecular imaging software that improves diagnostic precision in radiotheranostics.

Expert Quote
"Theranostics represents the future of medicine - where diagnosis and therapy converge for unmatched treatment accuracy.
Its role in oncology and beyond underscores the transition from generalized care to precision-guided healthcare,"
said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=49320

Market Drivers
• Increasing incidence of cancer and chronic diseases
• Growing adoption of radiopharmaceuticals and molecular imaging
• Advancements in AI-driven image analysis and companion diagnostics
• Rising government and private investment in personalized medicine R&D
• Expansion of PET and SPECT imaging infrastructure globally

Forecast and Outlook
The next decade will mark an era of precision oncology dominance, with theranostics enabling early diagnosis, real-time monitoring, and personalized dose delivery.
Integration of AI, big data analytics, and biomarker discovery will further enhance patient outcomes and accelerate drug development timelines.

The future of theranostics will expand beyond oncology into neurology, cardiology, and immunology, transforming chronic disease management through patient-specific targeting.
Emerging economies will play a crucial role as radiopharmacy networks and nuclear medicine centers expand globally.

Regional Insights
• North America: Largest market; strong nuclear medicine ecosystem and advanced healthcare infrastructure.
• Europe: Significant growth supported by EU investments in radiopharmaceutical production and clinical research.
• Asia-Pacific: Fastest-growing region; rising healthcare investment in precision imaging and molecular diagnostics.
• Latin America: Expanding diagnostic imaging network and partnerships in oncology care.
• Middle East & Africa: Gradual adoption driven by public-private healthcare modernization efforts.

Conclusion
The Global Theranostics Market stands at the intersection of diagnostics, therapeutics, and data science, redefining precision medicine.
As healthcare moves toward personalized, value-based care, theranostics will play a pivotal role in optimizing treatment efficacy, patient safety, and healthcare economics.
Companies that innovate in radioligand development, AI-based imaging, and companion diagnostics will lead the next decade of growth.

This report is also available in the following languages : Japanese (セラノスティクス市場), Korean (테라노스틱스 시장), Chinese (治疗诊断市场), French (Marché de la théranostique), German (Theranostik-Markt), and Italian (Mercato della Teranostica), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/49320/theranostics-market#request-a-sample

Related Reports

Acute Radiation Syndrome Market
https://exactitudeconsultancy.com/reports/76062/acute-radiation-syndrome-market

US Addictions Therapeutics Market
https://exactitudeconsultancy.com/reports/76072/us-addictions-therapeutics-market

Pulmonary Surfactant Market
https://exactitudeconsultancy.com/reports/76083/pulmonary-surfactant-market

Alzheimer's Disease Treatment Market
https://exactitudeconsultancy.com/reports/76109/alzheimer-s-disease-treatment-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Theranostics Market to Reach USD 12.5 Billion by 2034 here

News-ID: 4264262 • Views:

More Releases from Exactitude Consultancy

Medical Imaging Displays Market to Reach USD 3.78 Billion by 2034
Medical Imaging Displays Market to Reach USD 3.78 Billion by 2034
The Global Medical Imaging Displays Market is set for steady growth as healthcare facilities invest in high-resolution, AI-enhanced displays to support precise diagnostics and surgical visualization. According to Exactitude Consultancy, the market, valued at USD 2.46 billion in 2024, is projected to reach USD 3.78 billion by 2034, growing at a CAGR of 4.3 % from 2025 to 2034. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49322 Rising diagnostic imaging
Anthrax Treatment Market to Reach USD 550.6 Million by 2034
Anthrax Treatment Market to Reach USD 550.6 Million by 2034
The Global Anthrax Treatment Market is expanding steadily, driven by increasing government initiatives for biodefense preparedness, ongoing R&D in vaccine development, and growing awareness about early detection of Bacillus anthracis infections. According to Exactitude Consultancy, the market, valued at USD 378.4 million in 2024, is projected to reach USD 550.6 million by 2034, growing at a CAGR of 3.8 % during the forecast period (2025-2034). Download Full PDF Sample Copy of
Veterinary Infusion Pumps Market to Reach USD 151.4 Million by 2034
Veterinary Infusion Pumps Market to Reach USD 151.4 Million by 2034
Pune, India, November 11, 2025 - The global Veterinary Infusion Pumps Market is projected to grow from USD 87.6 million in 2024 to USD 151.4 million by 2034, registering a CAGR of 5.7%, according to Exactitude Consultancy. Rising pet ownership, increased spending on animal healthcare, and technological advancements in smart fluid delivery systems are driving the market's rapid expansion. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49118 Key Takeaways • Market Size
Anal Fistula Treatment Market to Reach USD 867.5 Million by 2034
Anal Fistula Treatment Market to Reach USD 867.5 Million by 2034
The Global Anal Fistula Treatment Market is gaining significant traction due to the rising incidence of anorectal disorders and increasing patient preference for minimally invasive and sphincter-preserving procedures. According to Exactitude Consultancy, the market, valued at USD 528.9 million in 2024, is projected to reach USD 867.5 million by 2034, growing at a CAGR of 5.1 % between 2025 and 2034. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49915 Growing

All 5 Releases


More Releases for Theranostics

Theranostics Market in 2025 Detailed Study Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Theranostics Market -(Product (Diagnostic imaging, Radiopharmaceuticals, Biomarker screening and Software), Application (Prostate Cancer, Bone Metastasis, Other Cancers, Other Application), End-user (Hospitals & Cancer Care Centers, Theranostics Centers, and Research & Academic Centers)) Trends, Industry Competition Analysis, Revenue and Forecast To 2034." According to the latest research by InsightAce Analytic, the Global Theranostics Market Size is valued
Rising Cancer Prevalence Fuels Growth In The Theranostics Market Driver: Leading …
What combination of drivers is leading to accelerated growth in the theranostics market? The theranostics market is forecasted to grow due to an upward trend in cancer cases. Cancer, a disease characterized by unchecked cell growth affecting numerous organs, is a leading cause of considerable illness and death globally. Theranostics, combining therapeutic and diagnostic aspects, holds significant prospects in managing cancer and chronic illnesses. This methodology paves the way for tailored
Theranostics Market worth $4.3 billion by 2028
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall theranostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. Theranostics Market [https://www.marketsandmarkets.com/Market-Reports/theranostics-market-111696976.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] in terms of revenue was estimated to be worth $2.1 billion in 2023 and is poised to reach $4.3
Theranostics Market Worth $4.3 Billion | MarketsandMarkets Trademark
Theranostics Market in terms of revenue was estimated to be worth $2.1 billion in 2023 and is poised to reach $4.3 billion by 2028, growing at a CAGR of 15.5% from 2023 to 2028 Theranostics Market [https://www.marketsandmarkets.com/Market-Reports/theranostics-market-111696976.html?utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr] in terms of revenue was estimated to be worth $2.1 billion in 2023 and is poised to reach $4.3 billion by 2028, growing at a CAGR of 15.5% from 2023 to 2028 according to
Theranostics Market: Pioneering Precision Medicine into 2030
The Theranostics Market was valued USD 1.9 Billion in 2023 and projected to reach USD 5.4 Billion by 2030, growing at a CAGR of 16.2% during the forecast period of 2024-2030. The Theranostics Market report studies the competitive environment of the Theranostics Market based on company profiles and their efforts to increase product value and production. The Theranostics Market report discusses various factors driving or restraining the market, which will help
01-08-2020 | Health & Medicine
TMR
Theranostics Market Is Booming Worldwide Just Published
Global Theranostics Market: An Overview Theranostics is a new field of medicine which relies on targeted therapies to conduct specific targeted tests. These tests are mainly used for various forms of cancers. The key concern in the therapeutics involve patient centric care with the help of more personalised and precise approach. The technique relies on the use of diagnostic and therapeutic applications to form a single agent. The system is known